$ELVN
Enliven Therapeutics, Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · Burlingame, CA
ELVN chart
What traders are saying about $ELVN
Latest postsEnliven Therapeutics, Inc. news
- Weekly Recap: ENABLE-2 design set and relcobatinib named, Ball joins board
TradingView ·
- Enliven Therapeutics Stock Losses Widen As Phase 3 Trial Plan Gets FDA Alignment
Simply Wall St ·
- Enliven Therapeutics Stock In Focus After Wider Loss And FDA Trial Alignment
Yahoo Finance ·
- Enliven Therapeutics (ELVN) On FDA Trial Alignment And The Case For More Upside
Simply Wall St ·
- Enliven Therapeutics, Inc. (ELVN) Seasonal returns chart
Yahoo Finance UK ·
- Guggenheim maintains Enliven Therapeutics at Buy, keeps price target at $78
TradingView ·
- Guggenheim Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $78
Moomoo ·
- Enliven Therapeutics secures FDA agreement on ENABLE-2 trial design after stock ends session down 5.1%
Traders Union ·
- Enliven Therapeutics Q3 net loss widens on higher R&D spend
TradingView ·
- Enliven Therapeutics 3Q 2026: EPS ($0.36) — 10-Q Summary
TradingView ·
- Enliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business Update
Yahoo Finance ·
- Form 4 Enliven Therapeutics Inc: Lori Anne Kunkel (Director) For: 30 October
Investing.com Canada ·
Enliven Therapeutics, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$103.7M | -$89.0M | -$71.6M | -$37.7M |
| Diluted EPS | $-1.83 | $-1.89 | $-2.01 | $-12.05 |
| Total assets (year end) | $476.2M | $325.8M | $271.9M | $83.3M |
| Cash and equivalents (year end) | $98.9M | $124.1M | $100.1M | $75.5M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Enliven Therapeutics, Inc.
- Ticker
- ELVN (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Burlingame, CA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1672619
- Former names
- IMARA Inc.
Frequently asked questions
What exchange is Enliven Therapeutics, Inc. listed on?
Enliven Therapeutics, Inc. trades on the Nasdaq under the ticker symbol ELVN.
What industry is Enliven Therapeutics, Inc. in?
Enliven Therapeutics, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Enliven Therapeutics, Inc. headquartered?
Enliven Therapeutics, Inc.'s business address on file with the SEC is in Burlingame, CA.
When does Enliven Therapeutics, Inc.'s fiscal year end?
Enliven Therapeutics, Inc.'s fiscal year ends on December 31.